Details for New Drug Application (NDA): 016793
✉ Email this page to a colleague
The generic ingredient in CYTARABINE is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.
Summary for 016793
| Tradename: | CYTARABINE |
| Applicant: | Teva Parenteral |
| Ingredient: | cytarabine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 016793
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 21, 1987 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 016793
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Parenteral | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 016793-001 | Approved Prior to Jan 1, 1982 | ⤷ Get Started Free | ⤷ Get Started Free |
| Teva Parenteral | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 016793-002 | Approved Prior to Jan 1, 1982 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
